HIF-2α在肺动脉高压中的研究进展  

Recent advances of HIF-2αin pulmonary hypertension

作　　者：冀磊 李占强[1,2] 芦殿香 JI Lei;LI Zhan-qiang;LU Dian-xiang(Research Center for High Altitude Medicine,Qinghai University,Xining 810001,China;Key Laboratory of High Altitude Medicine(Ministry of Education),Key Laboratory of Application and Foundation for High Altitude Medicine Research in Qinghai Province(Qinghai-Utah Joint Research Key Lab for High Altitude Medicine),Xining 810001,China;Qinghai Provincial People's Hospital,Xining 810007,China)

机构地区：[1]青海大学高原医学研究中心,青海西宁810001 [2]高原医学教育部重点实验室、青海省高原医学应用基础重点实验室(青海-犹他高原医学联合重点实验室),青海西宁810001 [3]青海省人民医院,青海西宁810007

出　　处：《药学学报》2022年第2期277-286,共10页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金资助项目(81860768,82060786);青海省自然科学基金资助项目(2020-ZJ-784);2020年中国科学院西部之光项目(1.4)。

摘　　要：肺动脉高压(pulmonary hypertension,PH)是一种以肺血管阻力进行性增加、闭塞性血管重构为特征的疾病。低氧诱导因子-2α(hypoxia inducible factor-2 alpha,HIF-2α)是参与肺血管细胞异常增殖和肺血管重构过程的关键因子之一。本文主要从细胞水平、整体水平综述HIF-2α在PH发生中的作用及其机制,并对目前以HIF-2α为靶点治疗肺动脉高压的候选方案进行介绍,以期为PH发病机制的研究及有效治疗方法的筛选提供参考。Pulmonary hypertension(PH)is a kind of disease characterized by progressive increase of pulmonary vascular resistance and occlusive vascular remodeling.Hypoxic inductive factor-2α(HIF-2α)plays an important role in the abnormal proliferation of pulmonary vascular cells and pulmonary vascular remodeling.This review focuses on the role of HIF-2α in pulmonary hypertension at the cellular and the global level,and candidates targeting HIF-2α for the treatment of pulmonary hypertension,in order to better understand the pathogenesis of PH and find effective treatments.

关 键 词：低氧诱导因子-2α 肺动脉高压 内皮细胞 低氧诱导因子-1Α 治疗 

分 类 号：R966[医药卫生—药理学]